Study of NGM313 in Obese Participants

A Phase 1B, Single Center, Randomized, Open Label, Parallel Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single NGM313 Dose or Daily Oral Pioglitazone in Obese Participants With Insulin Resistance and Increased Liver Fat

The purpose of the study is to evaulate the safety, tolerability, and efficacy of NGM313 in obese participants

Inclusion Criteria:

• Body mass index (BMI) of 30-43 kg/m2
• Waist circumference > 40 inches in males or > 30 inches in females
• Normal ECG readings

Exclusion Criteria:

• Significant history or clinical manifestation of any significant metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder
• History of any known Congestive heart failure (CHF)
• History of macrovascular disease